LG Life Sciences

LG Life Sciences began research in genetic engineering in 1981 and has invested steadily in the life sciences ever since. This effort has already resulted in world-class technology and product capabilities. The company has focused R&D resources and know-how on three areas-pharmaceuticals, animal health and specialty chemicals. LG Life Sciences has developed and commercialized an array of pharmaceuticals over the years. These include interferon in 1989 (Intermax-gamma) and 1992 (Intermax-alpha), hepatitis B vaccine in 1992 (EUVAX BTM), human growth hormone in 1993 (EUTROPINTM), degenerative arthritis treatment in 2005 (HYRUAN PlusTM), rhFSH (recombinant human follicle stimulating hormone) in 2006 (FollitropeTM), and SR-hGH (Sustained Release-human Growth Hormone) in 2007 (DeclageTM). A company milestone was reached in 2003, when its next-generation quinolone antibiotic (FACTIVE) was approved by the FDA in the United States. LG Life Sciences has a vision to become a top-tier life sc...